0000927653false00009276532024-05-072024-05-070000927653us-gaap:CommonStockMember2024-05-072024-05-070000927653mck:A1.500NotesDue2025Member2024-05-072024-05-070000927653mck:A1.625NotesDue2026Member2024-05-072024-05-070000927653mck:A3.125NotesDue2029Member2024-05-072024-05-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 7, 2024
McKESSON CORPORATION
(Exact Name of Registrant as Specified in Charter)
| | | | | | | | | | | | | | |
| | | | |
| Delaware | | 1-13252 | | 94-3207296 |
(State or Other Jurisdiction
of Incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
6555 State Hwy 161
Irving, TX 75039
(Address of Principal Executive Offices, and Zip Code)
(972) 446-4800
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| | | | | |
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading
Symbol(s) | | Name of each exchange
on which registered |
| Common stock, $0.01 par value | | MCK | | New York Stock Exchange |
| | | | |
| 1.500% Notes due 2025 | | MCK25 | | New York Stock Exchange |
| 1.625% Notes due 2026 | | MCK26 | | New York Stock Exchange |
| 3.125% Notes due 2029 | | MCK29 | | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 7, 2024, McKesson Corporation (“Company”) reported the Company’s preliminary results for the quarter and fiscal year ended on March 31, 2024 which are attached hereto as Exhibit 99.1.
The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| | | | | | | | |
| | |
| Exhibit No. | | Description |
| |
| 99.1 | | | |
| 104 | | | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 7, 2024
| | | | | | | | |
| | |
| McKesson Corporation |
| |
| By: | /s/ Britt J. Vitalone |
| | Britt J. Vitalone |
| | Executive Vice President and |
| | Chief Financial Officer |
McKESSON CORPORATION REPORTS FISCAL 2024 FOURTH QUARTER
AND FULL YEAR RESULTS
Fourth Quarter Highlights:
•Consolidated revenues of $76.4 billion increased by 11%.
•Earnings per diluted share from continuing operations of $6.02 increased $0.31.
•Adjusted Earnings per Diluted Share of $6.18 decreased by 14%.
Full Year Highlights:
•Consolidated revenues of $309.0 billion increased by 12%.
•Earnings per diluted share from continuing operations of $22.39 decreased $2.66.
•Adjusted Earnings per Diluted Share of $27.44 increased by 6%.
•Cash flow from operations of $4.3 billion and Free Cash Flow of $3.6 billion.
Fiscal 2025 Outlook:
•Fiscal 2025 Adjusted Earnings per Diluted Share guidance range of $31.25 to $32.05 indicates 14% to 17% forecasted growth compared to the prior year.
•The Company does not forecast GAAP earnings per diluted share from continuing operations1.
IRVING, Texas, May 7, 2024 - McKesson Corporation (NYSE:MCK) today announced results for the fourth quarter and fiscal year ended March 31, 2024.
Fiscal 2024 Fourth Quarter and Full Year Result Summary
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Fourth Quarter | | Full Year |
| ($ in millions, except per share amounts) | | FY24 | | FY23 | | Change | | FY24 | | FY23 | | Change |
| Revenues | | $ | 76,355 | | | $ | 68,910 | | | 11 | % | | $ | 308,951 | | | $ | 276,711 | | | 12 | % |
Income from Continuing Operations 2 | | 791 | | | 787 | | | 1 | | | 3,002 | | | 3,563 | | | (16) | |
Adjusted Earnings 2,3 | | 813 | | | 992 | | | (18) | | | 3,679 | | | 3,689 | | | — | |
Earnings per Diluted Share 2 | | 6.02 | | | 5.71 | | | 5 | | | 22.39 | | | 25.05 | | | (11) | |
Adjusted Earnings per Diluted Share 2,3 | | 6.18 | | | 7.19 | | | (14) | | | 27.44 | | | 25.94 | | | 6 | |
1 See below under "Fiscal 2025 Outlook" for full explanation 2 Reflects continuing operations attributable to McKesson, net of tax 3 Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions, reconciliation schedules, and Schedule 2 |
"McKesson reported fourth quarter results, marking the close to a strong fiscal 2024, underpinned by continued momentum across the enterprise," said Brian Tyler, chief executive officer. "The results underscore the execution against our company priorities, differentiated capabilities within the oncology and biopharma services platforms, and the sustained strength of our core distribution businesses. We continue to leverage the breadth and depth of our assets, delivering meaningful outcomes for our customers, partners, patients, and communities. I want to thank all McKesson employees for their efforts, dedication, and contributions."
"Looking ahead to fiscal 2025, we are well-positioned to further expand on the extensive range of our assets and capabilities, execute against our strategic initiatives, foster sustainable growth, and create long-term value for all stakeholders," said Mr. Tyler. "We are excited about the opportunities ahead as we advance health outcomes for all."
Fourth quarter revenues were $76.4 billion, an increase of 11% from a year ago. Revenue increases were primarily driven by growth in the U.S. Pharmaceutical segment, resulting from increased prescription volumes, including higher volumes from specialty products, retail national account customers, and GLP-1 medications.
Fourth quarter earnings per diluted share from continuing operations was $6.02 compared to $5.71 a year ago, an increase of $0.31. Full year earnings per diluted share from continuing operations was $22.39 compared to $25.05 a year ago, a decrease of $2.66.
Fourth quarter Adjusted Earnings per Diluted Share was $6.18 compared to $7.19 a year ago, a decrease of 14%, driven by a higher tax rate, partially offset by a lower share count and growth in the U.S. Pharmaceutical segment. Full year Adjusted Earnings per Diluted Share was $27.44 compared to $25.94 a year ago, an increase of 6%, led by growth in the U.S. Pharmaceutical and Prescription Technology Solutions segments and a lower share count, partially offset by higher corporate expenses.
For the full year, McKesson returned $3.3 billion of cash to shareholders, which included $3.0 billion of common stock repurchases and $314 million of dividend payments. During the fiscal year, McKesson generated cash from operations of $4.3 billion, and invested $687 million in capital expenditures, resulting in Free Cash Flow of $3.6 billion.
Business Highlights
•McKesson continued to advance and expand its oncology and biopharma services platforms.
◦In the past year, McKesson's CoverMyMeds business helped patients save more than $8.8 billion on brand and specialty medications, helped to prevent 10.7 million prescriptions from being abandoned due to affordability challenges, and helped patients access their medicine more than 94 million times.
◦The Sarah Cannon Research Institute joint venture announced a collaboration with AstraZeneca aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials.
•McKesson launched a pilot initiative aimed at advancing health equity in underserved communities. Avondale, Ohio was selected as the first activation site to support access to essential pharmacy services and help tackle healthcare disparities.
•McKesson received three awards and recognitions.
◦Named by Fortune as one of America's Most Innovative Companies.
◦Recognized by Newsweek as one of America's Greatest Workplaces for Women in 2024.
◦Recognized by DiversityComm Media as a 2024 Best of the Best Top Women Employer.
U.S. Pharmaceutical Segment
Fourth Quarter
•Revenues were $68.8 billion, an increase of 12%, driven by increased prescription volumes, including higher volumes from specialty products, retail national account customers, and GLP-1 medications.
•Segment Operating Profit was $1.1 billion. Adjusted Segment Operating Profit was $901 million, an increase of 5%, driven by growth in the distribution of specialty products to providers and health systems and increased contributions from our generics program.
Full Year
•Revenues were $278.7 billion, an increase of 16%, driven by increased prescription volumes, including higher volumes from specialty products, retail national account customers, and GLP-1 medications.
•Segment Operating Profit was $2.8 billion. Adjusted Segment Operating Profit was $3.3 billion, an increase of 7%, driven by growth in the distribution of specialty products to providers and health systems and increased contributions from our generics program.
Prescription Technology Solutions Segment
Fourth Quarter
•Revenues were $1.2 billion, flat to the prior year, driven by growth in the technology services business, offset by lower contributions from the third-party logistics business.
•Segment Operating Profit was $188 million. Adjusted Segment Operating Profit was $212 million, a decrease of 3%, driven by higher investments and expenses to support future growth across the biopharma services platform.
Full Year
•Revenues were $4.8 billion, an increase of 9%, driven by increased prescription volumes in the technology services and third-party logistics businesses.
•Segment Operating Profit was $835 million. Adjusted Segment Operating Profit was $837 million, an increase of 23%, driven by higher demand for access solutions, principally prior authorization services led by increased prescription volumes.
Medical-Surgical Solutions Segment
Fourth Quarter
•Revenues were $2.8 billion, an increase of 6%, driven by growth in the primary and extended care businesses, including higher volumes of illness season testing, partially offset by lower contribution from kitting, storage, and distribution of ancillary supplies for the U.S. government's COVID-19 vaccine program.
•Segment Operating Profit was $213 million. Adjusted Segment Operating Profit was $248 million, flat to the prior year, driven by lower contribution from kitting, storage, and distribution of ancillary supplies for the U.S. government's COVID-19 vaccine program, offset by growth in the primary and extended care businesses, including higher volumes of illness season testing.
Full Year
•Revenues were $11.3 billion, an increase of 2%, driven by growth in the primary and extended care businesses, partially offset by lower contribution from kitting, storage, and distribution of ancillary supplies for the U.S. government's COVID-19 vaccine program.
•Segment Operating Profit was $952 million. Adjusted Segment Operating Profit was $1.0 billion, a decrease of 12%, driven by lower contribution from kitting, storage, and distribution of ancillary supplies for the U.S. government's COVID-19 vaccine program, partially offset by growth in the primary and extended care businesses.
International Segment
Fourth Quarter
•Revenues were $3.5 billion, an increase of 6%, driven by higher pharmaceutical distribution volumes in the Canadian business.
•Segment Operating Profit was $70 million. Adjusted Segment Operating Profit was $94 million, an increase of 18%, driven by higher pharmaceutical distribution volumes in the Canadian business.
Full Year
•Revenues were $14.1 billion, a decrease of 31%, driven by Fiscal 2023 divestitures within McKesson's European business.
•Segment Operating Profit was $319 million. Adjusted Segment Operating Profit was $378 million, a decrease of 24%, driven by Fiscal 2023 divestitures within McKesson's European business.
Fiscal 2025 Outlook
McKesson does not provide forward-looking guidance on a GAAP basis as the Company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.
McKesson continues its focused execution on company priorities, leveraging its assets and capabilities to drive sustainable growth. McKesson anticipates Fiscal 2025 Adjusted Earnings per Diluted Share of $31.25 to $32.05 reflecting continued operating momentum, a strong financial position, and a balanced approach to capital deployment.
Additional modeling considerations will be provided in the earnings call presentation.
Conference Call Details
McKesson has scheduled a conference call for today, Tuesday, May 7th at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at investor.mckesson.com.
Upcoming Investor Event
McKesson management will be participating in the following investor conference:
•BofA Securities 2024 Healthcare Conference, May 16, 2024
The audio webcast, and a complete listing of upcoming events for the investment community, including details and updates, will be available on McKesson's Investor Relations website.
Non-GAAP Financial Measures
GAAP refers to the U.S. generally accepted accounting principles. This press release includes GAAP financial measures as well as Non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Other Income, Adjusted Interest Expense, Adjusted Income Tax Expense, Adjusted Earnings, Adjusted Earnings per Diluted Share, Adjusted Segment Operating Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses, Adjusted Operating Profit, FX-Adjusted results and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the “Supplemental Non-GAAP Financial Information” section of the accompanying financial statement tables for the definitions and usefulness of the Company’s Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.
Cautionary Statements
This earnings release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology. The discussion of financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, intentions, and the potential impact of new relationships or initiatives may also include forward-looking statements. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by law, we undertake no obligation to update or revise our forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such
risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.
These risk factors include, but are not limited to: we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we might experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we may be unsuccessful in achieving our strategic growth objectives; we are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to limitations that could impede the growth of our data services business; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have had difficulties in sourcing or selling products due to a variety of causes; we might be adversely impacted as a result of our distribution of generic pharmaceuticals; we might be adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events; we may be adversely affected by global climate change or by legal, regulatory, or market responses to such change; and governance issues and regulations, including those related to social issues, climate change, and sustainability, and stakeholder response thereto may have an adverse effect on our business, financial condition, and results of operations and damage our reputation.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
Contacts:
Rachel Rodriguez, 469-260-0556 (Investors)
Rachel.Rodriguez@McKesson.com
Media Relations
MediaRelations@McKesson.com
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (GAAP)
(unaudited)
(in millions, except per share amounts)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | Year Ended March 31, | | |
| 2024 | | 2023 | | Change | | 2024 | | 2023 | | Change |
| Revenues | $ | 76,355 | | | $ | 68,910 | | | 11 | % | | $ | 308,951 | | | $ | 276,711 | | | 12 | % |
| Cost of sales | (72,770) | | | (65,844) | | | 11 | | | (296,123) | | | (264,353) | | | 12 | |
| Gross profit | 3,585 | | | 3,066 | | | 17 | | | 12,828 | | | 12,358 | | | 4 | |
| Selling, distribution, general, and administrative expenses | (2,189) | | | (1,964) | | | 11 | | | (8,657) | | | (7,776) | | | 11 | |
| Claims and litigation charges, net | (149) | | | 3 | | | — | | | (147) | | | 8 | | | — | |
| | | | | | | | | | | |
| Restructuring, impairment, and related charges, net | (31) | | | (125) | | | (75) | | | (115) | | | (209) | | | (45) | |
| Total operating expenses | (2,369) | | | (2,086) | | | 14 | | | (8,919) | | | (7,977) | | | 12 | |
| Operating income | 1,216 | | | 980 | | | 24 | | | 3,909 | | | 4,381 | | | (11) | |
| Other income, net | 34 | | | 31 | | | 10 | | | 132 | | | 497 | | | (73) | |
| | | | | | | | | | | |
| Interest expense | (80) | | | (79) | | | 1 | | | (252) | | | (248) | | | 2 | |
| Income from continuing operations before income taxes | 1,170 | | | 932 | | | 26 | | | 3,789 | | | 4,630 | | | (18) | |
| Income tax expense | (340) | | | (106) | | | 221 | | | (629) | | | (905) | | | (30) | |
| Income from continuing operations | 830 | | | 826 | | | — | | | 3,160 | | | 3,725 | | | (15) | |
| Loss from discontinued operations, net of tax | — | | | — | | | — | | | — | | | (3) | | | (100) | |
| Net income | 830 | | | 826 | | | — | | | 3,160 | | | 3,722 | | | (15) | |
| Net income attributable to noncontrolling interests | (39) | | | (39) | | | — | | | (158) | | | (162) | | | (2) | |
| Net income attributable to McKesson Corporation | $ | 791 | | | $ | 787 | | | 1 | % | | $ | 3,002 | | | $ | 3,560 | | | (16) | % |
| | | | | | | | | | | |
Earnings (loss) per common share attributable to McKesson Corporation (a) | | | | | | | | | | | |
| Diluted | | | | | | | | | | | |
| Continuing operations | $ | 6.02 | | | $ | 5.71 | | | 5 | % | | $ | 22.39 | | | $ | 25.05 | | | (11) | % |
| Discontinued operations | — | | | — | | | — | | | — | | | (0.02) | | | (100) | |
| Total | $ | 6.02 | | | $ | 5.71 | | | 5 | % | | $ | 22.39 | | | $ | 25.03 | | | (11) | % |
| | | | | | | | | | | |
| Basic | | | | | | | | | | | |
| Continuing operations | $ | 6.06 | | | $ | 5.75 | | | 5 | % | | $ | 22.54 | | | $ | 25.25 | | | (11) | % |
| Discontinued operations | — | | | — | | | — | | | — | | | (0.02) | | | (100) | |
| Total | $ | 6.06 | | | $ | 5.75 | | | 5 | % | | $ | 22.54 | | | $ | 25.23 | | | (11) | % |
| | | | | | | | | | | |
| Dividends declared per common share | $ | 0.62 | | | $ | 0.54 | | | 15 | % | | $ | 2.40 | | | $ | 2.09 | | | 15 | % |
| | | | | | | | | | | |
| Weighted-average common shares outstanding | | | | | | | | | | | |
| Diluted | 131.6 | | | 138.0 | | | (5) | % | | 134.1 | | | 142.2 | | | (6) | % |
| Basic | 130.7 | | | 136.9 | | | (5) | | | 133.2 | | | 141.1 | | | (6) | |
(a)Certain computations may reflect rounding adjustments.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to our applicable filings with the SEC for additional disclosures including our Quarterly Reports on Form 10-Q for fiscal 2024 and 2023 as well as our
Annual Report on Form 10-K for fiscal 2024 and 2023.
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions, except per share amounts)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | Year Ended March 31, | | |
| 2024 | | 2023 | | Change | | 2024 | | 2023 | | Change |
| Income from continuing operations (GAAP) | $ | 830 | | | $ | 826 | | | — | % | | $ | 3,160 | | | $ | 3,725 | | | (15) | % |
| Net income attributable to noncontrolling interests (GAAP) | (39) | | | (39) | | | — | | | (158) | | | (162) | | | (2) | |
| Income from continuing operations attributable to McKesson Corporation (GAAP) | 791 | | | 787 | | | 1 | | | 3,002 | | | 3,563 | | | (16) | |
| Pre-tax adjustments: | | | | | | | | | | | |
| Amortization of acquisition-related intangibles | 63 | | | 66 | | | (5) | | | 249 | | | 236 | | | 6 | |
Transaction-related expenses and adjustments (1) (2) (3) | 17 | | | 35 | | | (51) | | | 10 | | | (123) | | | 108 | |
| LIFO inventory-related adjustments | (246) | | | 32 | | | (869) | | | (157) | | | 1 | | | — | |
| Gains from antitrust legal settlements | (24) | | | — | | | — | | | (244) | | | (129) | | | 89 | |
Restructuring, impairment, and related charges, net (4) | 31 | | | 125 | | | (75) | | | 115 | | | 209 | | | (45) | |
Claims and litigation charges, net (5) | 149 | | | (3) | | | — | | | 147 | | | (8) | | | — | |
Other adjustments, net (6) (7) | 27 | | | 1 | | | — | | | 762 | | | (70) | | | — | |
| Income tax effect on pre-tax adjustments | 6 | | | (48) | | | 113 | | | (198) | | | 13 | | | — | |
| Net income attributable to noncontrolling interests effect on pre-tax adjustments | (1) | | | (3) | | | (67) | | | (7) | | | (3) | | | 133 | |
| Adjusted Earnings (Non-GAAP) | $ | 813 | | | $ | 992 | | | (18) | % | | $ | 3,679 | | | $ | 3,689 | | | — | % |
| | | | | | | | | | | |
Earnings per diluted common share from continuing operations attributable to McKesson Corporation (GAAP) (a) | $ | 6.02 | | | $ | 5.71 | | | 5 | % | | $ | 22.39 | | | $ | 25.05 | | | (11) | % |
| After-tax adjustments: | | | | | | | | | | | |
| Amortization of acquisition-related intangibles | 0.37 | | | 0.36 | | | 3 | | | 1.42 | | | 1.29 | | | 10 | |
| Transaction-related expenses and adjustments | 0.11 | | | 0.20 | | | (45) | | | 0.15 | | | (0.52) | | | 129 | |
| LIFO inventory-related adjustments | (1.38) | | | 0.18 | | | (867) | | | (0.86) | | | 0.01 | | | — | |
| Gains from antitrust legal settlements | (0.13) | | | — | | | — | | | (1.35) | | | (0.67) | | | 101 | |
| Restructuring, impairment, and related charges, net | 0.19 | | | 0.69 | | | (72) | | | 0.66 | | | 1.13 | | | (42) | |
| Claims and litigation charges, net | 0.85 | | | 0.05 | | | — | | | 0.82 | | | 0.02 | | | — | |
| Other adjustments, net | 0.15 | | | — | | | — | | | 4.21 | | | (0.37) | | | — | |
Adjusted Earnings per Diluted Share (Non-GAAP) (a) (b) | $ | 6.18 | | | $ | 7.19 | | | (14) | % | | $ | 27.44 | | | $ | 25.94 | | | 6 | % |
| | | | | | | | | | | |
| Diluted weighted-average common shares outstanding | 131.6 | | | 138.0 | | | (5) | % | | 134.1 | | | 142.2 | | | (6) | % |
(a)Certain computations may reflect rounding adjustments.
(b)Adjusted earnings per diluted share on an FX-adjusted basis for the three months and year ended March 31, 2024 was $6.18 and $27.46, respectively, which excludes the foreign currency exchange effect of nil and $0.02, respectively.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Earnings (Non-GAAP) and Adjusted Earnings per Diluted Share (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | Year Ended March 31, | | |
| 2024 | | 2023 | | Change | | 2024 | | 2023 | | Change |
| Gross profit (GAAP) | $ | 3,585 | | | $ | 3,066 | | | 17 | % | | $ | 12,828 | | | $ | 12,358 | | | 4 | % |
| Pre-tax adjustments: | | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| LIFO inventory-related adjustments | (246) | | | 32 | | | (869) | | | (157) | | | 1 | | | — | |
| Gains from antitrust legal settlements | (24) | | | — | | | — | | | (244) | | | (129) | | | 89 | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Adjusted Gross Profit (Non-GAAP) | $ | 3,315 | | | $ | 3,098 | | | 7 | % | | $ | 12,427 | | | $ | 12,230 | | | 2 | % |
| | | | | | | | | | | |
| Total operating expenses (GAAP) | $ | (2,369) | | | $ | (2,086) | | | 14 | % | | $ | (8,919) | | | $ | (7,977) | | | 12 | % |
| Pre-tax adjustments: | | | | | | | | | | | |
| Amortization of acquisition-related intangibles | 63 | | | 66 | | | (5) | | | 249 | | | 236 | | | 6 | |
Transaction-related expenses and adjustments (1) (2) | 12 | | | 26 | | | (54) | | | (12) | | | 10 | | | (220) | |
| | | | | | | | | | | |
| | | | | | | | | | | |
Restructuring, impairment, and related charges, net (4) | 31 | | | 125 | | | (75) | | | 115 | | | 209 | | | (45) | |
Claims and litigation charges, net (5) | 149 | | | (3) | | | — | | | 147 | | | (8) | | | — | |
Other adjustments, net (6) | 27 | | | — | | | — | | | 762 | | | 26 | | | — | |
| Adjusted Operating Expenses (Non-GAAP) | $ | (2,087) | | | $ | (1,872) | | | 11 | % | | $ | (7,658) | | | $ | (7,504) | | | 2 | % |
| | | | | | | | | | | |
| Other income, net (GAAP) | $ | 34 | | | $ | 31 | | | 10 | % | | $ | 132 | | | $ | 497 | | | (73) | % |
| Pre-tax adjustments: | | | | | | | | | | | |
| | | | | | | | | | | |
Transaction-related expenses and adjustments (3) | — | | | — | | | — | | | — | | | (142) | | | (100) | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
Other adjustments, net (7) | — | | | 1 | | | (100) | | | — | | | (96) | | | (100) | |
| Adjusted Other Income (Non-GAAP) | $ | 34 | | | $ | 32 | | | 6 | % | | $ | 132 | | | $ | 259 | | | (49) | % |
| | | | | | | | | | | |
| Interest expense (GAAP) | $ | (80) | | | $ | (79) | | | 1 | % | | $ | (252) | | | $ | (248) | | | 2 | % |
| Pre-tax adjustments: | | | | | | | | | | | |
| | | | | | | | | | | |
| Transaction-related expenses and adjustments | 5 | | | 9 | | | (44) | | | 22 | | | 9 | | | 144 | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Adjusted Interest Expense (Non-GAAP) | $ | (75) | | | $ | (70) | | | 7 | % | | $ | (230) | | | $ | (239) | | | (4) | % |
| | | | | | | | | | | |
| Income tax expense (GAAP) | $ | (340) | | | $ | (106) | | | 221 | % | | $ | (629) | | | $ | (905) | | | (30) | % |
| Tax adjustments: | | | | | | | | | | | |
| Amortization of acquisition-related intangibles | (13) | | | (14) | | | (7) | | | (53) | | | (51) | | | 4 | |
| Transaction-related expenses and adjustments | (2) | | | (6) | | | (67) | | | 12 | | | 51 | | | (76) | |
| LIFO inventory-related adjustments | 64 | | | (8) | | | 900 | | | 41 | | | — | | | — | |
| Gains from antitrust legal settlements | 6 | | | — | | | — | | | 63 | | | 34 | | | 85 | |
| Restructuring, impairment, and related charges, net | (6) | | | (30) | | | (80) | | | (27) | | | (49) | | | (45) | |
| Claims and litigation charges, net | (37) | | | 10 | | | (470) | | | (37) | | | 11 | | | (436) | |
| Other adjustments, net | (6) | | | — | | | — | | | (197) | | | 17 | | | — | |
| Adjusted Income Tax Expense (Non-GAAP) | $ | (334) | | | $ | (154) | | | 117 | % | | $ | (827) | | | $ | (892) | | | (7) | % |
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Gross Profit (Non-GAAP), Adjusted Operating Expenses (Non-GAAP), Adjusted Other Income (Non-GAAP), Adjusted Interest Expense (Non-GAAP), and Adjusted Income Tax Expense (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | | | | | | | | | | | | | |
| | 2024 | | 2023 | | As reported | | As adjusted | | Change |
| As reported (GAAP) | | Adjustments | | As adjusted (Non-GAAP) | | As reported (GAAP) | | Adjustments | | As adjusted (Non-GAAP) | | Foreign currency effects | | FX-Adjusted (Non-GAAP) | | Foreign currency effects | | FX-Adjusted (Non-GAAP) | | As reported (GAAP) | | As adjusted (Non-GAAP) | | As reported
FX-Adjusted
(Non-GAAP) | | As adjusted
FX-Adjusted
(Non-GAAP) |
| REVENUES | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| U.S. Pharmaceutical | $ | 68,790 | | | $ | — | | | $ | 68,790 | | | $ | 61,676 | | | $ | — | | | $ | 61,676 | | | $ | — | | | $ | 68,790 | | | $ | — | | | $ | 68,790 | | | 12 | % | | 12 | % | | 12 | % | | 12 | % |
| Prescription Technology Solutions | 1,180 | | | — | | | 1,180 | | | 1,182 | | | — | | | 1,182 | | | — | | | 1,180 | | | — | | | 1,180 | | | — | | | — | | | — | | | — | |
| Medical-Surgical Solutions | 2,837 | | | — | | | 2,837 | | | 2,689 | | | — | | | 2,689 | | | — | | | 2,837 | | | — | | | 2,837 | | | 6 | | | 6 | | | 6 | | | 6 | |
| International | 3,548 | | | — | | | 3,548 | | | 3,363 | | | — | | | 3,363 | | | (1) | | | 3,547 | | | (1) | | | 3,547 | | | 6 | | | 6 | | | 5 | | | 5 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revenues | $ | 76,355 | | | $ | — | | | $ | 76,355 | | | $ | 68,910 | | | $ | — | | | $ | 68,910 | | | $ | (1) | | | $ | 76,354 | | | $ | (1) | | | $ | 76,354 | | | 11 | % | | 11 | % | | 11 | % | | 11 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
OPERATING PROFIT (4) | | | | | | | | | | | | | | | | |
U.S. Pharmaceutical (5) | $ | 1,059 | | | $ | (158) | | | $ | 901 | | | $ | 764 | | | $ | 97 | | | $ | 861 | | | $ | — | | | $ | 1,059 | | | $ | — | | | $ | 901 | | | 39 | % | | 5 | % | | 39 | % | | 5 | % |
| Prescription Technology Solutions | 188 | | | 24 | | | 212 | | | 166 | | | 52 | | | 218 | | | — | | | 188 | | | — | | | 212 | | | 13 | | | (3) | | | 13 | | | (3) | |
| Medical-Surgical Solutions | 213 | | | 35 | | | 248 | | | 234 | | | 14 | | | 248 | | | — | | | 213 | | | — | | | 248 | | | (9) | | | — | | | (9) | | | — | |
| International | 70 | | | 24 | | | 94 | | | 43 | | | 37 | | | 80 | | | — | | | 70 | | | — | | | 94 | | | 63 | | | 18 | | | 63 | | | 18 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Subtotal | 1,530 | | | (75) | | | 1,455 | | | 1,207 | | | 200 | | | 1,407 | | | — | | | 1,530 | | | — | | | 1,455 | | | 27 | | | 3 | | | 27 | | | 3 | |
Corporate expenses, net (5) | (280) | | | 87 | | | (193) | | | (196) | | | 47 | | | (149) | | | — | | | (280) | | | — | | | (193) | | | 43 | | | 30 | | | 43 | | 30 | |
| Income from continuing operations before interest expense and income taxes | $ | 1,250 | | | $ | 12 | | | $ | 1,262 | | | $ | 1,011 | | | $ | 247 | | | $ | 1,258 | | | $ | — | | | $ | 1,250 | | | $ | — | | | $ | 1,262 | | | 24 | % | | — | % | | 24 | % | | — | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| OPERATING PROFIT AS A % OF REVENUES | | | | | | | | | | | | | | | | |
| U.S. Pharmaceutical | 1.54 | % | | | | 1.31 | % | | 1.24 | % | | | | 1.40 | % | | | | 1.54 | % | | | | 1.31 | % | | 30 | bp | | (9) | bp | | 30 | bp | | (9) | bp |
| Prescription Technology Solutions | 15.93 | | | | | 17.97 | | | 14.04 | | | | | 18.44 | | | | | 15.93 | | | | | 17.97 | | | 189 | | | (47) | | | 189 | | | (47) | |
| Medical-Surgical Solutions | 7.51 | | | | | 8.74 | | | 8.70 | | | | | 9.22 | | | | | 7.51 | | | | | 8.74 | | | (119) | | | (48) | | | (119) | | | (48) | |
| International | 1.97 | | | | | 2.65 | | | 1.28 | | | | | 2.38 | | | | | 1.97 | | | | | 2.65 | | | 69 | | | 27 | | | 69 | | | 27 | |
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Segment Operating Profit (Non-GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-GAAP), FX-Adjusted (Non-GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Year Ended March 31, | | | | | | | | | | | | | | | | |
| | 2024 | | 2023 | | As reported | | As adjusted | | Change |
| As reported (GAAP) | | Adjustments | | As adjusted (Non-GAAP) | | As reported (GAAP) | | Adjustments | | As adjusted (Non-GAAP) | | Foreign currency effects | | FX-Adjusted (Non-GAAP) | | Foreign currency effects | | FX-Adjusted (Non-GAAP) | | As reported (GAAP) | | As adjusted (Non-GAAP) | | As reported
FX-Adjusted
(Non-GAAP) | | As adjusted
FX-Adjusted
(Non-GAAP) |
| REVENUES | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| U.S. Pharmaceutical | $ | 278,739 | | $ | — | | | $ | 278,739 | | $ | 240,616 | | $ | — | | | $ | 240,616 | | $ | — | | | $ | 278,739 | | $ | — | | | $ | 278,739 | | 16 | % | | 16 | % | | 16 | % | | 16 | % |
| Prescription Technology Solutions | 4,769 | | — | | | 4,769 | | 4,387 | | — | | | 4,387 | | — | | | 4,769 | | — | | | 4,769 | | 9 | | | 9 | | | 9 | | | 9 | |
| Medical-Surgical Solutions | 11,313 | | — | | | 11,313 | | 11,110 | | — | | | 11,110 | | — | | | 11,313 | | — | | | 11,313 | | 2 | | | 2 | | | 2 | | | 2 | |
| International | 14,130 | | — | | | 14,130 | | 20,598 | | — | | | 20,598 | | 323 | | | 14,453 | | 323 | | | 14,453 | | (31) | | | (31) | | | (30) | | | (30) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revenues | $ | 308,951 | | $ | — | | | $ | 308,951 | | $ | 276,711 | | $ | — | | | $ | 276,711 | | $ | 323 | | | $ | 309,274 | | $ | 323 | | | $ | 309,274 | | 12 | % | | 12 | % | | 12 | % | | 12 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
OPERATING PROFIT (4) | | | | | | | | | | | | | | | | |
U.S. Pharmaceutical (3) (5) (6) | $ | 2,786 | | | $ | 529 | | | $ | 3,315 | | | $ | 3,206 | | | $ | (100) | | | $ | 3,106 | | | $ | — | | | $ | 2,786 | | | $ | — | | | $ | 3,315 | | | (13) | % | | 7 | % | | (13) | % | | 7 | % |
Prescription Technology Solutions (1) | 835 | | | 2 | | | 837 | | | 566 | | | 113 | | | 679 | | | — | | | 835 | | | — | | | 837 | | | 48 | | | 23 | | | 48 | | | 23 | |
| Medical-Surgical Solutions | 952 | | | 67 | | | 1,019 | | | 1,117 | | | 42 | | | 1,159 | | | — | | | 952 | | | — | | | 1,019 | | | (15) | | | (12) | | | (15) | | | (12) | |
International (2) | 319 | | | 59 | | | 378 | | | 136 | | | 362 | | | 498 | | | 6 | | | 325 | | | 8 | | | 386 | | | 135 | | | (24) | | | 139 | | | (22) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Subtotal | 4,892 | | | 657 | | | 5,549 | | | 5,025 | | | 417 | | | 5,442 | | | 6 | | | 4,898 | | | 8 | | | 5,557 | | | (3) | | | 2 | | | (3) | | | 2 | |
Corporate expenses, net (2) (5) (7) (8) | (851) | | | 203 | | | (648) | | | (147) | | | (310) | | | (457) | | | (1) | | | (852) | | | (1) | | | (649) | | | 479 | | | 42 | | | 480 | | | 42 | |
| Income from continuing operations before interest expense and income taxes | $ | 4,041 | | | $ | 860 | | | $ | 4,901 | | | $ | 4,878 | | | $ | 107 | | | $ | 4,985 | | | $ | 5 | | | $ | 4,046 | | | $ | 7 | | | $ | 4,908 | | | (17) | % | | (2) | % | | (17) | % | | (2) | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| OPERATING PROFIT AS A % OF REVENUES | | | | | | | | | | | | | | | | |
| U.S. Pharmaceutical | 1.00 | % | | | | 1.19 | % | | 1.33 | % | | | | 1.29 | % | | | | 1.00 | % | | | | 1.19 | % | | (33) | bp | | (10) | bp | | (33) | bp | | (10) | bp |
| Prescription Technology Solutions | 17.51 | | | | | 17.55 | | | 12.90 | | | | | 15.48 | | | | | 17.51 | | | | | 17.55 | | | 461 | | | 207 | | | 461 | | | 207 | |
| Medical-Surgical Solutions | 8.42 | | | | | 9.01 | | | 10.05 | | | | | 10.43 | | | | | 8.42 | | | | | 9.01 | | | (163) | | | (142) | | | (163) | | | (142) | |
| International | 2.26 | | | | | 2.68 | | | 0.66 | | | | | 2.42 | | | | | 2.25 | | | | | 2.67 | | | 160 | | | 26 | | | 159 | | | 25 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Segment Operating Profit (Non-GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-GAAP), FX-Adjusted (Non-GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
McKESSON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions, except per share amounts)
| | | | | | | | | | | |
| March 31, 2024 | | March 31, 2023 |
| ASSETS | | | |
| Current assets | | | |
| Cash and cash equivalents | $ | 4,583 | | | $ | 4,678 | |
| Receivables, net | 21,622 | | | 19,410 | |
| Inventories, net | 21,139 | | | 19,691 | |
| | | |
| Prepaid expenses and other | 626 | | | 513 | |
| Total current assets | 47,970 | | | 44,292 | |
| Property, plant, and equipment, net | 2,316 | | | 2,177 | |
| Operating lease right-of-use assets | 1,729 | | | 1,635 | |
| Goodwill | 10,132 | | | 9,947 | |
| Intangible assets, net | 2,110 | | | 2,277 | |
| Other non-current assets | 3,186 | | | 1,992 | |
| Total assets | $ | 67,443 | | | $ | 62,320 | |
| | | |
| LIABILITIES AND DEFICIT |
| Current liabilities | | | |
| Drafts and accounts payable | $ | 47,097 | | | $ | 42,490 | |
| | | |
| Current portion of long-term debt | 50 | | | 968 | |
| Current portion of operating lease liabilities | 295 | | | 299 | |
| | | |
| Other accrued liabilities | 4,915 | | | 4,200 | |
| Total current liabilities | 52,357 | | | 47,957 | |
| Long-term debt | 5,579 | | | 4,626 | |
| Long-term deferred tax liabilities | 917 | | | 1,387 | |
| Long-term operating lease liabilities | 1,466 | | | 1,402 | |
| Long-term litigation liabilities | 6,113 | | | 6,625 | |
| Other non-current liabilities | 2,610 | | | 1,813 | |
| | | |
| McKesson Corporation stockholders’ deficit | | | |
| Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding | — | | | — | |
Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at March 31, 2024 and 2023, respectively | 3 | | | 3 | |
| Additional paid-in capital | 8,048 | | | 7,747 | |
| Retained earnings | 14,978 | | | 12,295 | |
| Accumulated other comprehensive loss | (881) | | | (905) | |
| | | |
Treasury shares, at cost, 148 and 141 shares at March 31, 2024 and 2023, respectively | (24,119) | | | (20,997) | |
| Total McKesson Corporation stockholders’ deficit | (1,971) | | | (1,857) | |
| Noncontrolling interests | 372 | | | 367 | |
| Total deficit | (1,599) | | | (1,490) | |
| Total liabilities and deficit | $ | 67,443 | | | $ | 62,320 | |
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in millions)
| | | | | | | | | | | |
| | Year Ended March 31, |
| | 2024 | | 2023 |
| OPERATING ACTIVITIES | | | |
| Net income | $ | 3,160 | | | $ | 3,722 | |
| Adjustments to reconcile to net cash provided by operating activities: | | | |
| Depreciation | 253 | | | 248 | |
| Amortization | 382 | | | 360 | |
| Long-lived asset impairment charges | 43 | | | 72 | |
| Deferred taxes | (603) | | | (20) | |
| Charges (credits) associated with last-in, first-out inventory method | (157) | | | 1 | |
| Non-cash operating lease expense | 228 | | | 249 | |
| Gain from sales of businesses and investments | (17) | | | (211) | |
| | | |
| Provision for bad debts | 819 | | | 45 | |
| Other non-cash items | 233 | | | 253 | |
| Changes in assets and liabilities, net of acquisitions: | | | |
| Receivables | (2,954) | | | (1,082) | |
| Inventories | (1,294) | | | (1,259) | |
| Drafts and accounts payable | 4,587 | | | 3,788 | |
| Operating lease liabilities | (339) | | | (338) | |
| Taxes | 331 | | | 363 | |
| Litigation liabilities | (395) | | | (1,088) | |
| Other | 37 | | | 56 | |
| Net cash provided by operating activities | 4,314 | | | 5,159 | |
| | | |
| INVESTING ACTIVITIES | | | |
| Payments for property, plant, and equipment | (431) | | | (390) | |
| Capitalized software expenditures | (256) | | | (168) | |
| Acquisitions, net of cash, cash equivalents, and restricted cash acquired | (272) | | | (867) | |
| Proceeds from sales of businesses and investments, net | 47 | | | 1,077 | |
| Other | (160) | | | (194) | |
| Net cash used in investing activities | (1,072) | | | (542) | |
| | | |
| FINANCING ACTIVITIES | | | |
| Proceeds from short-term borrowings | 19,964 | | | 8,450 | |
| Repayments of short-term borrowings | (19,964) | | | (8,450) | |
| Proceeds from issuances of long-term debt | 991 | | | 997 | |
| Repayments of long-term debt | (288) | | | (1,274) | |
| Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt | (647) | | | — | |
| | | |
| Common stock transactions: | | | |
| Issuances | 116 | | | 163 | |
| Share repurchases | (3,025) | | | (3,638) | |
| Dividends paid | (314) | | | (292) | |
| | | |
| Other | (175) | | | (324) | |
| Net cash used in financing activities | (3,342) | | | (4,368) | |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 6 | | | 25 | |
| Cash, cash equivalents, and restricted cash classified as Assets held for sale | — | | | 470 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (94) | | | 744 | |
| Cash, cash equivalents, and restricted cash at beginning of period | 4,679 | | | 3,935 | |
| Cash, cash equivalents, and restricted cash at end of period | 4,585 | | | 4,679 | |
Less: Restricted cash at end of period included in Prepaid expenses and other | (2) | | | (1) | |
| | | |
Cash and cash equivalents at end of period | $ | 4,583 | | | $ | 4,678 | |
McKESSON CORPORATION
RECONCILIATION OF GAAP CASH FLOW TO FREE CASH FLOW (NON-GAAP)
(unaudited)
(in millions)
| | | | | | | | | | | | | | | | | |
| | Year Ended March 31, | | |
| | 2024 | | 2023 | | Change |
| GAAP CASH FLOW CATEGORIES | | | | | |
| Net cash provided by operating activities | $ | 4,314 | | | $ | 5,159 | | | (16) | % |
| Net cash used in investing activities | (1,072) | | | (542) | | | 98 | |
| Net cash used in financing activities | (3,342) | | | (4,368) | | | (23) | |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 6 | | | 25 | | | (76) | |
| Cash, cash equivalents, and restricted cash classified as Assets held for sale | — | | | 470 | | | (100) | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $ | (94) | | | $ | 744 | | | (113) | % |
| | | | | |
| FREE CASH FLOW (NON-GAAP) | | | | | |
| Net cash provided by operating activities | $ | 4,314 | | | $ | 5,159 | | | (16) | % |
| Payments for property, plant, and equipment | (431) | | | (390) | | | 11 | |
| Capitalized software expenditures | (256) | | | (168) | | | 52 | |
| Free Cash Flow (Non-GAAP) | $ | 3,627 | | | $ | 4,601 | | | (21) | % |
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
For more information relating to the Free Cash Flow (Non-GAAP) definition, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
McKESSON CORPORATION
FINANCIAL STATEMENT NOTES
(1)Transaction-related expenses and adjustments for the year ended March 31, 2024 includes a pre-tax gain of $78 million ($58 million after-tax) related to fair value remeasurement of the contingent consideration liability recognized as part of our acquisition of Rx Savings Solutions, LLC. The gain, within Prescription Technology Solutions, resulted from remeasurement of the liability to fair value at the end of each reporting period based on the estimated amount and timing of projected operational and financial information and the probability of achievement of performance milestones. This gain is included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(2)Transaction-related expenses and adjustments for the year ended March 31, 2023 includes pre-tax net gains of $66 million ($35 million after-tax) related to an agreement to sell certain of our European businesses to the PHOENIX Group which closed on October 31, 2022. Pre-tax gains for the year ended March 31, 2023 of $306 million ($275 million after-tax) are included within Corporate expenses, net, and charges (pre-tax and after-tax) of $240 million are included within International. These pre-tax gains and charges are primarily to remeasure assets and liabilities held for sale to fair value less costs to sell, including the effect of accumulated other comprehensive income balances associated with the disposal group, and are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(3)Transaction-related expenses and adjustments for the year ended March 31, 2023 includes a pre-tax gain of $142 million ($105 million after-tax) related to the exit of an investment in equity securities within U.S. Pharmaceutical. This gain is included under "other income, net" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(4)Restructuring, impairment, and related charges, net for the three months and year ended March 31, 2024 includes pre-tax charges of $31 million ($25 million after-tax) and $115 million ($88 million after-tax), respectively, primarily within Corporate expenses, net, International, and U.S. Pharmaceutical. The three months and year ended March 31, 2023 includes pre-tax charges of $125 million ($95 million after-tax) and $209 million ($160 million after-tax), respectively, primarily within Prescription Technology Solutions, Corporate expenses, net, and U.S. Pharmaceutical. These charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(5)Claims and litigation charges, net for the three months and year ended March 31, 2024 includes pre-tax charges of $149 million ($112 million after-tax) related to our estimated liability for opioid-related claims of a nationwide class of acute care hospitals. We recorded charges of $75 million ($56 million after-tax) within Corporate expenses, net and $74 million ($56 million after-tax) within U.S. Pharmaceutical. These charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(6)Other adjustments, net for the year ended March 31, 2024 includes a pre-tax provision for bad debts of $725 million ($536 million after-tax) within U.S. Pharmaceutical related to the bankruptcy of our customer, Rite Aid Corporation (including certain of its subsidiaries, “Rite Aid”). Management believes this charge is not reflective of allowances recorded in the normal course of business operations and is related to Rite Aid's bankruptcy reorganization, and therefore is excluded from the determination of our adjusted results (Non-GAAP). This charge represents the remaining trade accounts receivable balance due from Rite Aid prior to its bankruptcy petition filing and is included under “total operating expenses” in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(7)Other adjustments, net for the year ended March 31, 2023 includes a pre-tax gain of $97 million ($72 million after-tax) within Corporate expenses, net from termination of fixed interest rate swaps accounted for as cash flow hedges. Management believes this gain is not part of the normal course of business operations and is therefore excluded from the determination of our adjusted results (Non-GAAP). This gain is included under "other income, net" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(8)Termination of Tax Receivable Agreement ("TRA") with Change Healthcare for the year ended March 31, 2023 consists of a pre-tax gain of $126 million ($93 million after-tax) within Corporate expenses, net, related to a cash payment received as a result of an exercise of the option by Change Healthcare Inc. ("Change") pursuant to the TRA for early termination of the agreement. We entered into this agreement as part of the formation of a joint venture with Change, from which McKesson has since exited. This gain was recorded in “Other income, net” in the Condensed Consolidated Statements of Operations (GAAP) provided in Schedule 1 of the accompanying financial statement tables.
McKESSON CORPORATION
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION
In an effort to provide investors with additional information regarding the Company's financial results as determined by generally accepted accounting principles ("GAAP"), McKesson Corporation (the "Company" or "we") also presents the following Non-GAAP measures in this press release.
•Adjusted Gross Profit (Non-GAAP): We define Adjusted Gross Profit as GAAP gross profit, excluding transaction-related expenses and adjustments, last-in, first-out (“LIFO”) inventory-related adjustments, gains from antitrust legal settlements, and other adjustments.
•Adjusted Operating Expenses (Non-GAAP): We define Adjusted Operating Expenses as GAAP total operating expenses, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
•Adjusted Other Income (Non-GAAP): We define Adjusted Other Income as GAAP other income (expense), net, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, and other adjustments.
•Adjusted Interest Expense (Non-GAAP): We define Adjusted Interest Expense as GAAP interest expense, excluding transaction-related expenses and adjustments related to net interest expense incurred from cross-currency swaps used to hedge the changes in the fair value of the Company's foreign currency-denominated notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The foreign currency-denominated notes were previously designated as non-derivative net investment hedges of portions of the Company's net investments in its now-divested European businesses against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar.
•Adjusted Income Tax Expense (Non-GAAP): We define Adjusted Income Tax Expense as GAAP income tax benefit (expense), excluding the income tax effects of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments. Income tax effects are calculated in accordance with Accounting Standards Codification ("ASC") 740, “Income Taxes,” which is the same accounting principle used by the Company when presenting its GAAP financial results.
•Adjusted Earnings (Non-GAAP): We define Adjusted Earnings as GAAP income from continuing operations attributable to McKesson, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments, as well as the related income tax effects for each of these items, as applicable.
•Adjusted Earnings per Diluted Share (Non-GAAP): We define Adjusted Earnings per Diluted Share as GAAP earnings per diluted common share from continuing operations attributable to McKesson, excluding per share impacts of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments, as well as the related income tax effects for each of these items, as applicable, divided by diluted weighted-average shares outstanding.
•Adjusted Segment Operating Profit (Non-GAAP) and Adjusted Segment Operating Profit Margin (Non-GAAP): We define Adjusted Segment Operating Profit as GAAP segment operating profit, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, and other adjustments. We define Adjusted Segment Operating Profit Margin as Adjusted Segment Operating Profit (Non-GAAP) divided by GAAP segment revenues.
•Adjusted Corporate Expenses (Non-GAAP): We define Adjusted Corporate Expenses as GAAP corporate expenses, net, excluding transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
•Adjusted Operating Profit (Non-GAAP): We define Adjusted Operating Profit as GAAP income from continuing operations before interest expense and income taxes, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
The following provides further details regarding the adjustments made to our GAAP financial results to arrive at our Non-GAAP measures as defined above:
Amortization of acquisition-related intangibles - Amortization charges for intangible assets directly related to business combinations and the formation of joint ventures.
Transaction-related expenses and adjustments - Transaction, integration, and other expenses that are directly related to business combinations, the formation of joint ventures, divestitures, and other transaction-related costs including initial public offering costs. Examples include transaction closing costs, professional service fees, legal fees, severance charges, retention payments and employee relocation expenses, facility or other exit-related expenses, certain fair value adjustments including deferred revenues, contingent consideration and inventory, recoveries of acquisition-related expenses or post-closing expenses, net interest expense impact of hedging foreign currency-denominated notes, bridge loan fees and gains or losses on business combinations, and divestitures of businesses that do not qualify as discontinued operations.
LIFO inventory-related adjustments - LIFO inventory-related non-cash charges or credit adjustments.
Gains from antitrust legal settlements - Net cash proceeds representing the Company’s share of antitrust legal settlements.
Restructuring, impairment, and related charges - Restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted as well as long-lived asset impairments. Such charges may include employee severance, retention bonuses, facility closure or consolidation costs, lease or contract termination costs, asset impairments, accelerated depreciation and amortization, and other related expenses. The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, integration of acquired businesses, and/or company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of our underlying business, which include normal levels of reinvestment in the business. Any credit adjustments due to subsequent changes in estimates are also excluded from adjusted results.
Claims and litigation charges - Adjustments to certain of the Company’s reserves, including those related to estimated probable settlements for its controlled substance monitoring and reporting, and opioid-related claims, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred. This also may include charges or credits for general non-operational claims not directly related to our ongoing business.
Other adjustments - The Company evaluates the nature and significance of transactions qualitatively and quantitatively on an individual basis and may include them in the determination of our adjusted results from time to time. While not all-inclusive, other adjustments may include: other asset impairments; gains or losses from debt extinguishment; and other similar substantive and/or infrequent items as deemed appropriate.
The Company evaluates the aforementioned Non-GAAP measures on a periodic basis and updates the definitions from time to time. The evaluation considers both the quantitative and qualitative aspects of the Company’s presentation of Non-GAAP adjusted results. A reconciliation of McKesson’s GAAP financial results to Non-GAAP financial results is provided in Schedules 2 and 3 of the financial statement tables included with this press release.
•FX-Adjusted (Non-GAAP): McKesson also presents its GAAP financial results and adjusted results (Non-GAAP) on an FX-Adjusted basis. To present our financial results on an FX-Adjusted basis, we convert current year period results of our operations in foreign countries, which are recorded in local currencies, into U.S. dollars by applying the average foreign currency exchange rates of the comparable prior year period. To present Adjusted Earnings per Diluted Share on an FX-Adjusted basis, we estimate the impact of foreign currency rate fluctuations on the Company’s noncontrolling interests and adjusted income tax expense, which may vary from quarter to quarter. The supplemental FX-Adjusted information of the Company’s GAAP financial results and adjusted results (Non-GAAP) is provided in Schedule 3 of the financial statement tables included with this press release.
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
•Free Cash Flow (Non-GAAP): We define free cash flow as net cash provided by (used in) operating activities less payments for property, plant, and equipment and capitalized software expenditures, as disclosed in our condensed consolidated statements of cash flows. A reconciliation of McKesson’s GAAP financial results to Free Cash Flow (Non-GAAP) is provided in Schedule 6 of the financial statement tables included with this press release.
The Company believes the presentation of Non-GAAP measures provides useful supplemental information to investors with regard to its operating performance, as well as assists with the comparison of its past financial performance to the Company’s future financial results. Moreover, the Company believes that the presentation of Non-GAAP measures assists investors’ ability to compare its financial results to those of other companies in the same industry. However, the Company's Non-GAAP measures used in the press tables may be defined and calculated differently by other companies in the same industry.
The Company internally uses both GAAP and Non-GAAP financial measures in connection with its own financial planning and reporting processes. Management utilizes Non-GAAP financial measures when allocating resources, deploying capital, as well as assessing business performance, and determining employee incentive compensation. The Company conducts its businesses internationally in local currencies, including Canadian dollars, Euro, and British pound sterling. As a result, the comparability of our results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. We present FX-Adjusted information to provide a framework for assessing how our business performed excluding the estimated effect of foreign currency exchange rate fluctuations. We believe free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, re-investment opportunities, strategic acquisitions, share repurchases, dividend payments, or other strategic uses of cash. Nonetheless, Non-GAAP adjusted results and related Non-GAAP measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.
v3.24.1.u1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=mck_A1.500NotesDue2025Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=mck_A1.625NotesDue2026Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=mck_A3.125NotesDue2029Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
McKesson (NYSE:MCK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
McKesson (NYSE:MCK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
